Aspirin for Primary Prevention of Cardiovascular Events in Diabetes
Still an Open Question
- Author Affiliations: Department of Clinical Pharmacology and Epidemiology, Consorzio Mario Negri Sud, S. Maria Imbaro, Italy.
Since this article does not have an abstract, we have provided the first 150 words of the full text.
- KEYWORDS:
- AGING
- ASPIRIN
- CARDIOVASCULAR DISEASES
- DATA INTERPRETATION, STATISTICAL
- DIABETES MELLITUS TYPE 02
- DRUG THERAPY
- ISCHEMIC ATTACK, TRANSIENT
- MORTALITY
- MYOCARDIAL ISCHEMIA
- PERIPHERAL VASCULAR DISEASES
- PLATELET AGGREGATION INHIBITORS
- STROKE
Published online November 9, 2008 (doi:10.1001/jama.2008.625).
The use of aspirin for primary prevention of cardiovascular events in individuals with diabetes is widely recommended by existing guidelines, but the evidence supporting its efficacy is surprisingly scarce.1 Recommendations seem based mainly on extrapolations from data from other high-risk groups, rather than on solid data derived from studies conducted specifically in patients with diabetes. Indeed, an increasing amount of evidence suggests that the efficacy of antiplatelet therapy in patients with diabetes may be lower than in individuals without diabetes.2
In this issue of JAMA, Ogawa and colleagues3 report the results of the JPAD trial (Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes), specifically designed to address the issue of antiplatelet therapy for the primary prevention of cardiovascular events in diabetes. The trial included 2539 patients with type 2 diabetes and without a history of atherosclerotic disease …
